Development of solid lipid gene delivery system [Katı lipit gen taşıyıcı sistem geliştirilmesi]

Abstract

As a natural result of the progresses made in the recombinant DNA technology, the gene treatment has been brought forward for the improvement of genetic disorders. The purpose of the gene therapy is the treatment of the infection and genetic disorders with the introduction of new genetic materials among cells taken from the body. The objective of our study is to develop a new gene carrier system that can bind the DNA through electrostatic interaction by cationic solid lipid nanoparticulate (SLN) system with the help of a cationic lipid. In preparation of the SLNs, two different lipids including Mono-, di- and triglyceride mixtures (Gelucire 50/13 Pastilles) and Glycerol distearate (Precirol ATO 5) were selected as lipid matrixes. The particle sizes of the prepared cationic solid lipid particles were found to be between 50.55 ± 0.12 and 168.2 ± 0.35 nm. Their zeta potentials which constitute of an important characteristic for the stability were determined to be between -50.2 ± 0.16 and +37.1 ± 0.63 mV. Increasing the ratio of cationic lipids in SLN have been observed to increase the zeta potentials and the toxic properties on HEK 293 cells of SLNs. The DNA binding abilities of SLNs were found to be varied